 |
 |
 |
David Feldman
Academic Appointments
Appointment
Organization
Emeritus (Active) Professor
Member
|
|
|
Research Interests
Steroid hormones act by binding to intracellular receptors which regulate the expression of specific genes in target cells. My group is studying a number of aspects that relate molecular and cellular events of hormone action at the receptor level to clinically relevant questions. Some of the current projects are as follows:
1. Elucidation of the molecular basis of hereditary vitamin D resistant rickets, a genetic disease due to mutations in the vitamin D receptor.
2. Analysis of the endocrinologic mechanisms regulating vitamin D receptor expression and thereby modulating target organ sensitivity to the actions of vitamin D and its analogs.
3. Investigation of the role of vitamin D as a differentiating and antiproliferative agent with the potential to affect malignant cells, specifically prostate cancer.
4. Study of genetic variations in the vitamin D receptor gene and inheritance of low bone mass in relation to the development of osteoporosis.
Publications
-
Swami S,
Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D
"Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer."
J Nutr
2007;
137:
1:
205S-10S
More »
-
Krishnan AV,
Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM, Feldman D
"Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer."
J Steroid Biochem Mol Biol
2007;
More »
-
Wang J,
Malloy PJ, Feldman D
"Interactions of the vitamin D receptor with the corepressor hairless: Analysis of hairless mutants in atrichia with papular lesions."
J Biol Chem
2007;
More »
-
Feldman D,
Krishnan A, Moreno J, Swami S, Peehl DM, Srinivas S
"Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer."
Nutr Rev
2007;
65:
8 Pt 2:
S113-5
More »
-
Peng L,
Wang J, Malloy PJ, Feldman D
"The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells."
Int J Cancer
2007;
More »